Novavax
NVAX
325 hedge funds and large institutions have $1.75B invested in Novavax in 2022 Q2 according to their latest regulatory filings, with 55 funds opening new positions, 95 increasing their positions, 102 reducing their positions, and 106 closing their positions.
0.72% less ownership
Funds ownership: 44.16% → 43.44% (-0.72%)
7% less repeat investments, than reductions
Existing positions increased: 95 | Existing positions reduced: 102
14% less call options, than puts
Call options by funds: $353M | Put options by funds: $413M
15% less funds holding
Funds holding: 381 → 325 (-56)
30% less capital invested
Capital invested by funds: $2.49B → $1.75B (-$741M)
48% less first-time investments, than exits
New positions opened: 55 | Existing positions closed: 106
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$42.1M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$25.8M |
| 3 |
State Street
Boston,
Massachusetts
|
+$24.4M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
+$22.4M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$19.9M |
Top Sellers
NVAX Hedge Fund Activity: Q2 2022 in Review
325 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Novavax (NVAX) for Q2 2022, worth a combined $1.75B — down 30% from $2.49B a quarter earlier.
Sellers outnumbered buyers: 106 funds closed out of NVAX and 55 opened new positions — a net loss of 51 holders — while 102 trimmed existing stakes and 95 added.
The largest buyer was Citigroup, adding an estimated $42.1M. The largest seller was Susquehanna International Group, cutting an estimated $53.3M.
- 325 institutional investors held Novavax (NVAX) as of Q2 2022, down from 381 in Q1 2022.
- Funds reported $1.75B of Novavax stock for Q2 2022, down 30% quarter-over-quarter.
- 55 funds opened new Novavax positions in Q2 2022 and 106 closed out, a net change of -51 holders.
- The largest Novavax buyer in Q2 2022 was Citigroup, an estimated $42.1M added.
- The largest Novavax seller in Q2 2022 was Susquehanna International Group, an estimated $53.3M sold.
Based on aggregated 13F filings for Q2 2022.